Details for adverse event reporting can be found at the bottom of this page.

Kerendia is indicated for the treatment of chronic kidney disease (Stages 3 and 4 with albuminuria) associated with type 2 diabetes in adult patients.
Intended for a Great Britain Healthcare Professional audience only

404 - Page not found

The page you requested could not be found on this server.

There could be several reasons for this:

  • For technical reasons the page you are looking for may have been moved to a new address (URL).
  • You have entered the page address (URL) manually.
  • The page you requested may currently not be available.

 

Reporting adverse events and quality complaints

 

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 2500 or Email: pvuk@bayer.com

Further information is available on the 'contact' tab at www.bayer.co.uk.

 

© 2023 Bayer plc

This website contains information on Kerendia (finerenone), which is based on the Summary of Product Characteristics (SmPC).
Intended for a Great Britain Healthcare Professional audience only

This website was developed and fully funded by Bayer

RP-KER-GB-0143 | Date of preparation September 2023